THOUSAND OAKS, Calif., Nov. 1, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast investor meeting at the American Heart Association (AHA) Scientific Sessions 2012 on Tuesday, Nov. 6, at 7:00 p.m. Pacific Standard Time. Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team and clinical investigators, will participate at the investor meeting to discuss data being presented at AHA.
Live audio of the investor meeting will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public.
The webcast of the investor meeting, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability, and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 72 hours after the event.
About AmgenAmgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen. CONTACT: Amgen, Thousand Oaks Christine Regan, 805-559-0718 (media) Arvind Sood, 805-447-1060 (investors) (Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO) SOURCE Amgen